Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;4(6):345-9.
doi: 10.1593/tlo.11145. Epub 2011 Dec 1.

P21-activated kinase 4 overexpression in metastatic gastric cancer patients

Hee Kyung Ahn  1 , Jiryeon Jang, Jeeyun Lee, Park Se Hoon, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Kyoung-Mee Kim, Won Ki Kang
Affiliations

P21-activated kinase 4 overexpression in metastatic gastric cancer patients

Hee Kyung Ahn et al. Transl Oncol. 2011 Dec.

Abstract

Introduction: P21-activated kinase 4 (PAK), a subfamily of serine/threonine kinases originally known as a regulator of cytoskeletal dynamics and cell motility, has recently been revealed to play a key role in oncogenic signaling pathways. We studied the frequency and clinical features of PAK4-overexpressed metastatic gastric cancer.

Patients and methods: PAK4 overexpression was screened by Western blot in 18 human gastric cancer cell lines. Immunohistochemical staining of PAK4 protein was performed in tumor specimens of 49 metastatic gastric cancer patients who received palliative capecitabine/cisplatin as first-line treatment.

Results: PAK4 protein overexpression was detected strongly in five gastric cell lines (AGS, MGK-28, MKN-74, SNU-216, SNU-601) and weakly in four cell lines (KATOIII, MKN-1, SNU-620, and SNU-719). PAK4 knockdown by small interfering RNA induced apoptosis in PAK4-overexpressed AGS gastric cancer cells. Immunohistochemical staining revealed PAK4 overexpressions in 4 (8.1%) of 49 metastatic gastric cancer specimens. None of the four patients with PAK4(+) responded to capecitabine/cisplatin chemotherapy, and PAK4(+) gastric cancer patients had a trend of poorer survival compared with PAK(-)(P = .876).

Conclusions: We demonstrated PAK4 overexpression in a subset of gastric cancer patients, implicating a role in gastric cancer tumorigenesis. Its prognostic significance and efficacy as a drug target should be further studied.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Results of PAK4 expression level test using by Western blot. (B) Results of PAK4 knockdown by siRNA treatment in PAK4-overexpressed AGS cancer cell lines.
Figure 2
Figure 2
PAK4 overexpression in gastric cancer by immunohistochemical staining.
Figure 3
Figure 3
Comparison of overall survival according to PAK4 overexpression status in 49 gastric cancer patients.
See this image and copyright information in PMC

References

    1. Bae JM, Won JY, Jung KW, Park JG. Annual report of the Korean central cancer registry program 2000. Cancer Res Treat. 2002;34:77–83. - PubMed
    1. Callow MG, Clairvoyant F, Zhu S, Chryver B, Whyte DB, Bischoff JR, Jallal B, Smeal T. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem. 2002;277(1):550–558. - PubMed
    1. Qu J, Cammarano MS, Shi Q, Ha KC, de Lanerolle P, Minden A. Activated PAK4 regulates cell adhesion and anchorage-independent growth. Mol Cell Biol. 2001;21(10):3523–3533. - PMC - PubMed
    1. Callow MG, Zozulya S, Gishizky ML, Jallal B, Smeal T. PAK4 mediates morphological changes through the regulation of GEF-H1. J Cell Sci. 2005;118(pt 9):1861–1872. - PubMed
    1. Liu Y, Xiao H, Tian Y, Nekrasova T, Hao X, Lee HJ, Suh N, Yang CS, Minden A. The Pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol Cancer Res. 2008;6(7):1215–1224. - PMC - PubMed

LinkOut - more resources